Methods and compositions for targeting Tregs using CCR8 inhibitors
AssigneeNanjing Immunophage Biomedical Co., Ltd.
InventorsGuohuang Fan, Hongyu Yang, Kin Chiu Fong, Jianfei Wang
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
Claims12
A method of ameliorating symptoms of a condition characterized by abnormal or unwanted activity of regulatory T cells in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound, or a or a pharmaceutically acceptable salt, isotope, stereoisomer, tautomer, solvate, or combination thereof, wherein the compound is selected from the group consisting of:
A method of ameliorating symptoms of a condition mediated by abnormal or unwanted CCR8/CCL1 axis in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound or a or a pharmaceutically acceptable salt, isotope, stereoisomer, tautomer, solvate, or combination thereof, wherein the compound is selected from the group consisting of:
A method of ameliorating symptoms of a condition characterized by abnormal or unwanted activity of regulatory T cells in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound or a or a pharmaceutically acceptable salt, isotope, stereoisomer, tautomer, solvate, or combination thereof, wherein the compound is:
A method of ameliorating symptoms of a condition characterized by abnormal or unwanted activity of regulatory T cells in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound or a or a pharmaceutically acceptable salt, isotope, stereoisomer, tautomer, solvate, or combination thereof, wherein the compound is:
A method of ameliorating symptoms of a condition characterized by abnormal or unwanted activity of regulatory T cells in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound or a or a pharmaceutically acceptable salt, isotope, stereoisomer, tautomer, solvate, or combination thereof, wherein the compound is:
Dependencies are inferred from the claim text.